FY2025 EPS Estimates for Humana Raised by Leerink Partnrs

Key Points

• Leerink Partners has raised its FY2025 EPS estimate for Humana from $16.65 to $17.26, indicating a positive outlook for the insurance provider.
• Humana's stock received various ratings from analysts, with target prices ranging from $275.00 to $348.00, and a consensus rating of "Hold."
• The company recently reported $6.27 EPS for its latest quarter, slightly missing expectations, despite a revenue increase to $32.39 billion.

Humana Inc. (NYSE:HUM - Free Report) - Leerink Partnrs raised their FY2025 earnings estimates for shares of Humana in a research report issued to clients and investors on Wednesday, July 30th. Leerink Partnrs analyst W. Mayo now expects that the insurance provider will post earnings of $17.26 per share for the year, up from their previous forecast of $16.65. The consensus estimate for Humana's current full-year earnings is $16.47 per share. Leerink Partnrs also issued estimates for Humana's Q1 2026 earnings at $11.95 EPS, Q2 2026 earnings at $5.89 EPS, FY2026 earnings at $15.72 EPS, FY2027 earnings at $24.32 EPS and FY2029 earnings at $42.42 EPS.

Other analysts also recently issued reports about the company. Morgan Stanley cut their price objective on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research report on Thursday. Truist Financial reduced their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a research note on Wednesday, July 16th. Guggenheim assumed coverage on shares of Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective on the stock. Barclays set a $275.00 target price on shares of Humana and gave the company an "equal weight" rating in a report on Thursday. Finally, Robert W. Baird decreased their price target on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Humana has a consensus rating of "Hold" and a consensus target price of $281.62.

Humana Trading Down 1.1%

NYSE:HUM traded down $2.68 on Friday, reaching $247.19. The company's stock had a trading volume of 1,756,006 shares, compared to its average volume of 1,854,830. Humana has a 12-month low of $206.87 and a 12-month high of $382.72. The stock has a 50 day moving average price of $235.09 and a 200 day moving average price of $255.24. The firm has a market cap of $29.73 billion, a price-to-earnings ratio of 18.97, a price-to-earnings-growth ratio of 1.64 and a beta of 0.44. The company has a quick ratio of 1.91, a current ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company's revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.96 earnings per share.

Institutional Trading of Humana

A number of large investors have recently made changes to their positions in HUM. Vanguard Group Inc. lifted its holdings in Humana by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock worth $3,697,222,000 after buying an additional 1,143,662 shares during the last quarter. Dodge & Cox increased its holdings in shares of Humana by 5.5% in the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock valued at $2,845,830,000 after acquiring an additional 557,175 shares during the last quarter. Pzena Investment Management LLC raised its position in shares of Humana by 6.5% during the 2nd quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider's stock worth $996,664,000 after acquiring an additional 247,744 shares in the last quarter. Geode Capital Management LLC lifted its stake in Humana by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after purchasing an additional 63,562 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Humana by 29.8% in the fourth quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock valued at $608,348,000 after purchasing an additional 550,692 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.